Human epidermal growth factor receptor 2 (HER2) mutations have been increasingly recognized as a critical driver of malignancy in non-small cell lung cancer (NSCLC) (1), particularly in patients with advanced or metastatic disease. The gene discussed is ERBB2; the disease is metastatic neoplasm.